Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and vibrators.
Popular Articles

SCOTUS Ruling Reversing Decision From Sotomayor's Court Not Expected To Affect Nomination
The Supreme Court"s 5-4 reversal of a decision endorsed by a three-judge appellate panel that included Supreme Court nominee Sonia Sotomayor is attracting criticism from the judge"s conservative opponents but is not expected to have a significant effect on delaying her confirmation, the Washington Post reports. The appellate panel in 2008 upheld New Haven, Conn."s decision to discard a promotion test for firefighters after no blacks and only two Hispanics qualified for advancement after taking the test (Markon/Kane, Washington Post, 6/30). The panel"s ruling affirmed a lower court"s decision that the city had a right to discard the test based on a segment of civil rights law involving actions that have a "disparate impact" on minorities. A group of white and Hispanic firefighters who would have received promotions under the test sued, alleging reverse discrimination. Democrats and legal analysts said that Sotomayor was following legal precedent in the 2008 ruling and that it was the Supreme Court, which has the ability to exercise more discretion, that chose to make law by reversing the decision (Friedman, CongressDaily, 6/29). The Supreme Court typically reverses about 75% of the cases it reviews, according to legal experts. The court previously has reversed four of Sotomayor"s rulings and upheld three of her decisions, the Post reports. Tom Goldstein, a lawyer and founder of the SCOTUSblog Web site, said, "I don"t think it will persuade anybody who is inclined one way or another to change their views about Sotomayor" (Washington Post, 6/30). Sen. Charles Schumer (D-N.Y.), a member of the Senate Judiciary Committee, said, "The main charge against Sotomayor is that she will be an activist judge, but this decision clearly shows that she won"t." He said that the results of the case "won"t change things a wit," adding that "in fact, it bolsters (the claim) that she is mainstream" (CongressDaily, 6/29). Sen. Jeff Sessions (R-Ala.), the ranking Republican on the Senate Judiciary Committee, said the New Haven case "sharpens our focus on [Sotomayor"s] troubling speeches and writings" that "indicate ... that personal experiences and political views should influence a judge"s decisions." He added that the issue "will clearly be the subject of questioning" at Sotomayor"s confirmation hearing, which is scheduled to begin on Monday (Phillips, "The Caucus," New York Times, 6/29).
buy viagra
Non-Wovens As Scaffolds For Artificial Tissue
In future, cartilage, tendon and blood vessel tissue will be produced in the laboratory, with cells being grown on a porous frame, such as non-wovens. A new software program helps to characterize and optimize the non-wovens.
News of the day
Research Carried Out In Mice Will Contribute To The Study Of Hereditary Diseases That Lead To Blindness
Researchers of the University of Granada (Spain) have used a technique consisting of the induction of neuronal degeneration neuronal for intense light exposure in the mouse"s retina that will be helpful for the study of retinitis pigmentosa (RP), a group of hereditary diseases which lead to blindness and affect more than one million persons a year all over the world. In addition, the results of this research work could be very useful for the detection of new factors or molecules originated by microglial cells and related to degenerative processes of the retina.
Cardiovascular

FDA Advisory Committee Votes In Favor Of SAPHRIS(R) (asenapine) For Acute Bipolar I Disorder And Acute Schizophrenia

Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted unanimously in favor of SAPHRIS(R) (asenapine) sublingual tablets as effective and safe for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and in favor of use in acute treatment of schizophrenia in adults. If approved by FDA, SAPHRIS would be the first psychotropic drug to be approved initially for both of these indications. "We are very pleased with the outcome of today"s advisory committee meeting and appreciate the panel"s careful consideration of the efficacy and safety data for SAPHRIS," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "In clinical studies, SAPHRIS has demonstrated efficacy combined with an attractive metabolic safety profile. SAPHRIS has the potential to address a significant unmet need for patients with schizophrenia and bipolar I disorder, including patients starting treatment and those who need alternative treatment options when switching or re-initiating therapy. We will continue to work with FDA to bring SAPHRIS to the U.S. market as soon as possible so that patients can benefit from this new medication." While the FDA is not bound by the committee"s recommendations, the agency carefully considers them before making a final decision on approval. After reviewing the SAPHRIS data, the committee voted in favor of SAPHRIS as effective (by counts of 12/0/0 and 10/2/0, yes/no/abstain) and safe (12/0/0 and 10/0/2) for the bipolar I disorder and schizophrenia indications, respectively. In addition, the committee voted on the overall balance of safety and efficacy by counts of 12/0/0 and 9/1/2 for the bipolar I disorder and schizophrenia indications, respectively. The New Drug Application (NDA) for SAPHRIS includes efficacy data from a clinical trial program involving more than 3,000 patients in schizophrenia and bipolar mania trials, and is supported by safety data in 4,500 patients, with some treated for more than two years. In Europe, a Marketing Authorization Application (MAA) for asenapine, under the brand name SYCREST(R), is currently under review by the European Medicines Agency (EMEA) for the treatment of schizophrenia and manic episodes associated with bipolar I disorder. The application will follow the Centralized Procedure. Schering-Plough acquired asenapine in November 2007 through its acquisition of Organon BioSciences, which developed the product. About Schizophrenia Schizophrenia is a chronic, disabling brain disorder that is characterized by hallucinations, delusions and disordered thinking. The condition affects about 24 million people worldwide (or seven in every 1,000 adults in the population), including more than two million people in the United States and more than four million people in Europe. Although there are a number of medications available for patients, treatment success for any antipsychotic agent can be unpredictable because patients often respond differently to various medications. Among patients with schizophrenia who are being treated with antipsychotics, nearly three in four patients discontinue therapy within 18 months due to either poor tolerability or incomplete efficacy. Metabolic safety, including weight gain, elevation of lipid levels (dyslipidemia) and glucose dysregulation, is an important consideration with any antipsychotic treatment. Patients often need to switch treatments in order for physicians to balance effective treatment with the long-term safety of their patients. About Bipolar I Disorder Bipolar I disorder (also known as manic depression) is a chronic, episodic illness characterized by mania (episodes of elevated moods, extreme irritability, decreased sleep and increased energy), depression (overwhelming feelings of sadness, suicidal thoughts), or a combination of both. It is the sixth leading cause of disability in the world, affecting approximately 1 to 5 percent of adults, including 10 million Americans. About half of the patients with bipolar disorder who recover in response to treatment experience recurrence two years later. Patients may experience a high rate of failure due to lack of efficacy or side effects, including metabolic side effects. Poor tolerability frequently leads to treatment discontinuation even when the treatment is providing some benefit. To help manage this challenge, patients often receive multiple medications or need to switch treatments. About Schering-Plough Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough"s vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of, the commercial plans for and the potential market for SAPHRIS/SYCREST. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough"s forward-looking statements, including uncertainties in the regulatory process, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough"s Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the Company"s second quarter 2009 10-Q, filed July 24, 2009. Schering-Plough Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009